Breaking News, Collaborations & Alliances

Kintor, Visum Enter COVID-19 Manufacturing Partnership

To expand proxalutamide manufacturing for treatment of COVID-19 patients.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Kintor Pharmaceutical, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, has entered a partnership with Hainan Visum Pharmaceutical to expand proxalutamide manufacturing.   At present, Kintor Pharmaceutical is completing the Brazilian clinical trials of proxalutamide for treatment of male and female COVID-19 patients with mild or moderate symptoms and COVID-19 patients with severe symptoms. Preliminary data indicates that after proxalutamide...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters